0 evaluări0% au considerat acest document util (0 voturi)
54 vizualizări6 pagini
A-bulnesene is a sesquiterpenoid isolated from Pogostemon cablin. It showed a potent and concentration-dependent inhibitory effect on platelet-activating factor (PAF) and arachidonic acid (AA) induced rabbit platelet aggregation.
A-bulnesene is a sesquiterpenoid isolated from Pogostemon cablin. It showed a potent and concentration-dependent inhibitory effect on platelet-activating factor (PAF) and arachidonic acid (AA) induced rabbit platelet aggregation.
A-bulnesene is a sesquiterpenoid isolated from Pogostemon cablin. It showed a potent and concentration-dependent inhibitory effect on platelet-activating factor (PAF) and arachidonic acid (AA) induced rabbit platelet aggregation.
a-Bulnesene, a novel PAF receptor antagonist isolated
from Pogostemon cablin
Hui-Chun Hsu a,b , Wen-Chia Yang a , Wei-Jern Tsai c , Chien-Chih Chen c , Hui-Yu Huang d, * , Ying-Chieh Tsai a, * a Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan b Yangsen Biotechnology Co. Ltd, Taipei, Taiwan c National Research Institute of Chinese Medicines, Taipei, Taiwan d Department of Food Science, Nutrition, and Nutraceutical Biotechnology, Shih-Chien University, Taipei, Taiwan Received 13 March 2006 Available online 8 May 2006 Abstract a-Bulnesene is a sesquiterpenoid isolated from the water extract of Pogostemon cablin. It showed a potent and concentration-depen- dent inhibitory eect on platelet-activating factor (PAF) and arachidonic acid (AA) induced rabbit platelet aggregation. In a radioligand binding assay for the PAF receptor, a-bulnesene competitively inhibited [ 3 H]PAF binding to the PAF receptor with an IC 50 value of 17.62 5.68 lM. a-Bulnesene also dose-dependently inhibited PAF-induced intracellular Ca 2+ increase in uo-3/AM-loaded platelets (IC 50 values of 19.62 1.32 lM). Furthermore, a-bulnesene inhibited AA-induced thromboxane B 2 (TXB 2 ) formation and prostaglan- din E 2 (PGE 2 ) formation. These results indicate that the inhibitory eect of a-bulnesene on platelet aggregation was due to a dual activ- ity; specically the chemical blocked PAF-induced intracellular signal transduction and interfered with cyclooxygenase activity, which resulted in a decrease in thromboxane formation. This study is the rst to demonstrate that a-bulnesene is a PAF receptor antagonist as well as an anti-platelet aggregation agent. 2006 Elsevier Inc. All rights reserved. Keywords: a-Bulnesene; Pogostemon cablin; Sesquiterpenoid; Platelet aggregation; Platelet-activating factor (PAF); Arachidonic acid (AA) It is well recognized that platelet aggregation plays an important role in thrombosis and atherosclerosis. Mural thrombus formation can restrict the ow of blood to vital tissues or organs leading to peripheral cerebral or coronary ischemia. Evidence has indicated that platelets contribute signicantly to the etiology and pathogenesis of acute cor- onary syndrome, myocardial infraction, and embolismic stroke, which are major causes of death in developed coun- tries [1,2]. The rst step in the response of platelets to vas- cular injury is irreversible attachment to the altered surface followed by platelet activation [3]. This mainly takes place though the action of many agonists such as platelet-activat- ing factor (PAF), arachidonic acid (AA), and others. The activation of platelets can be counter-regulated by factors that attenuate or prevent these agonist-induced responses [2]. Anti-platelet agents can inhibit platelet activation by many mechanisms. One example is aspirin, which is a non-specic cyclooxygenase inhibitor that dampens the production of thromboxane A 2 (TXA 2 ). Aspirin has been shown to be clinically benecial in the treatment of throm- boembotic diseases. Previous studies have reported that the constituents of Melicope semecarpifolia root, aqueous extracts of plants (alfalfa, fresh nettle, and camonile) and the constituents of Panax notoginseng root show signicant eects on plate- let aggregation [46]. However, current anti-platelet drugs still have considerable limitations in their mode of action and ecacy. A greater understanding of platelet function at the molecular level will probably lead to the develop- ment of novel anti-platelet drugs [3]. 0006-291X/$ - see front matter 2006 Elsevier Inc. All rights reserved. doi:10.1016/j.bbrc.2006.05.006 * Corresponding authors. Fax: +886 2 28209226. E-mail addresses: maggieh@mail.usc.edu.tw (H.-Y. Huang), tsaiyc@ ym.edu.tw (Y.-C. Tsai). www.elsevier.com/locate/ybbrc Biochemical and Biophysical Research Communications 345 (2006) 10331038 BBRC The Chinese herb, Pogostemon cablin (Labiatae), is the aerial part of P. cablin Bentham and has been principally used to treat the common cold, vomiting, and diarrhea in China and the surrounding region. This plant is cultivated extensively in Indonesia, Malaysia, China, and Brazil for its essential oil (patchouli oil), which is important to the per- fumery industry [79]. Anumber of investigations have been carried out on the composition of the essential oil of P. cablin [10,11], and the presence of some sesquiterpenoids has been reported [12]. Sesquiterpenoids frequently occur as compo- nents of plant essential oils and have been shown to have various biological activities including anti-fungal, antioxi- dant, and anti-inammatory eects [1315]. Asmall oily ses- quiterpene, a-bulnesene, has been isolated fromthe essential oil of P. cablin (Fig. 1), and has shown a most potent inhib- itory eect on platelet aggregation. In the present study, we evaluated the anti-platelet mechanism of a-bulnesene and showed it to be a PAF receptor antagonist. Materials and methods Materials. a-Bulnesene was isolated from the essential oil of P. cablin and the structure was identied using GC/MS and 1 H NMR spectroscopy (Fig. 1). PAF, AA, uo-3/AM, indomethacin, and ethylenediaminetetra- acetic acid (EDTA, disodium salt) were purchased from Sigma Chemical (St. Louis, MO). The thromboxane B 2 (TXB 2 ) and prostaglandin E 2 (PGE 2 ) enzyme immunoassay kits were obtained from Cayman Chemical Co. [ 3 H]PAF (1-O-[ 3 H]octadecyl-2-acetyl-sn-glycero-3-phosphocholine), with a specic radioactivity of 120 Ci mmol 1 , a product of Perkin-Elmer Science, was dissolved in absolute ethanol and diluted with saline solution containing 2.5 mg mL 1 bovine serum albumin (BSA) immediately prior to use. All other chemicals were of the highest purity grade available. Preparation of the platelet suspension. The platelet suspension was prepared according to a procedure previously described with some mod- ications [16,17]. Blood was collected from the marginal ear vein of New Zealand White rabbits. The blood was then anticoagulated with acid cit- rate dextrose (ACD, 6:1, v/v) and centrifuged for 8 min at 1000g at room temperature. The upper portion was kept as platelet-rich plasma (PRP) after mixing with EDTA to a nal concentration of 5 mM. Platelets were obtained from the EDTA-mixed PRP by centrifugation for 12 min at 2000g. The platelet pellets were resuspended in Ca 2+ -free Tyrodes solu- tion, and then incubated with apyrase (1 U mL 1 ) for 15 min at 37 C. After centrifugation for 6 min at 2000g, the platelet pellets were nally suspended in Tyrodes solution with the following composition: NaCl (137 mM), KCl (2.8 mM), MgCl 2 (2 mM), NaH 2 PO 4 (0.33 mM), CaCl 2 (1 mM), glucose (5 mM), Hepes (10 mM), and BSA (0.35%) at pH 7.3. The concentration of platelets was adjusted to 2.5 10 8 platelets mL 1 . Measurement of platelet aggregation. Platelet aggregation was mea- sured turbidimetrically with a light-transmission Platelet Aggregation Chromogenic Kinetic System PACK4 (Helena Laboratories, Beaumont, TX, USA) with some modications [2]. The platelet suspension was stirred at 900 rev min 1 and incubated with an appropriate amount of isopro- panol (vehicle) or various concentrations of a-bulnesene in isopropanol at 37 C for 2 min. Aggregation was induced with PAF (5 nM) or AA (100 lM). The absorbance of the Tyrodes solution was taken as 0% aggregation and that of the platelet suspension as 100% aggregation. The extent of platelet aggregation was measured as the maximal increase in light transmission within 4 min after the addition of an inducer. When isopropanol was used as the solvent, the nal concentration was xed at 0.5% (v/v) to eliminate the eect of the solvent. All glassware was siliconized. [ 3 H]PAF receptor binding assay. This experiment was performed as detailed previously [18,19] with some modications. The reaction mixture consisted of 400 lL of platelet suspension, 50 lL of [ 3 H]PAF (0.2 nM, 100,000 dpm) with or without unlabeled PAF (1.5 lM), and 50 lL of sample or control solution. The reaction mixture was incubated at 4 C for 2 h and then 5 mL of BSA-containing saline solution was added to ter- minate the reaction. The free and bound ligands were separated by l- tration using a Whatman GF/C glass ber lter that had been presoaked with ice-cold water. The lters were rapidly washed with the same solution and then dried and placed into vials containing 10 mL of scintillation uid. Radioactivity was measured in a liquid scintillation counter (Beckman LS3801). The dierence between the total radioactivity of the bound [ 3 H]PAF in the absence and the presence of excess unlabeled PAF was dened as specic binding of the radio-labeled ligand. In this set of experiments, [ 3 H]PAF was incubated with dierent concentrations of PAF receptor antagonists, and the eect of the antagonist on the specic binding was expressed as a percentage inhibition of the control. The IC 50 value was dened as the nal concentration of the inhibitor required to block 50% of specic [ 3 H]PAF binding to rabbit platelet receptors. Measurement of intracellular calcium mobilization. This used a slight modication of a method published previously [2]. The platelets were pelleted from PRP and resuspended in Ca 2+ -free Tyrodes solution, then incubated with uo-3/AM (2 lM) at 37 C for 30 min. In order to prevent leakage of the dye, probenecid (2.5 mM) was added to the buers throughout the experiments [20]. After washing, the uo-3-loaded platelets were nally suspended in Ca 2+ -free Tyrodes solution without heparin at a concentration of 1.3 10 8 platelets mL 1 . The uo-3-loaded platelets were preincubated with an appropriate amount of isopropanol (control) or with various concentrations of a-bulnesene in isopropanol in the presence of extracellular calcium (1 mM) at 37 C for 2 min prior to the addition of PAF. Fluorescence (Ex 505 nm, Em 530 nm) was measured with a uo- rescence spectrophotometer (Model F4500; Hitachi, Tokyo, Japan). At the end of the experiment, the cells were treated with digitonin (20%) followed by the addition of 50 mM ethyleneglycol-bis(aminoethylether)- N,N-tetraacetic acid (EGTA) to obtain the maximal and minimal uo- rescence, respectively. [Ca 2+ ] i was calculated as described for uo-3/AM using the Ca 2+ -dye dissociation constant of 864 nM. Thromboxane B 2 and prostaglandin E 2 assay. Because TXA 2 is very unstable and rapidly converted to the more stable metabolite TXB 2 , we measured the amount of TXB 2 present. After challenge of the platelets with AA (100 lM) for 6 min, 1 mM ethylenediaminetetraacetic acid (EDTA) and 20 lM indomethacin were added to terminate the reaction. After centrifugation for 5 min at 4 C and 10,000g, the TXB 2 and PGE 2 in the supernatants were assayed using the appropriate EIA kit according to the procedure described by the manufacturer (Cayman). Statistics. All results were expressed as means standard error (SE). The statistical signicance was analyzed by Students t-test and the sig- nicance level set at P = 0.05. Results Eect of a-bulnesene on platelet aggregation The inhibitory eect of a-bulnesene on PAF- and AA- induced platelet aggregation was determined using 5 nM Fig. 1. The chemical structure of a-bulnesene. 1034 H.-C. Hsu et al. / Biochemical and Biophysical Research Communications 345 (2006) 10331038 PAF and 100 lM AA, which causes about 7080% aggregation of rabbit washed platelets and the IC 50 val- ues were calculated to be 24.47 2.45 lM and 42.47 5.97 lM, respectively. This result was concentra- tion-dependent and paralleled the inhibitory eect on platelet aggregation. Fifty micromolar a-bulnesene had the highest inhibition rate when assayed against PAF- and AA-induced platelet aggregation (Fig. 2). In the cytotoxicity assay, a-bulnesene (12.550 lM) did not show any toxicity against rabbit platelets even after 30 min of treatment (data not shown), and this indicated that the inhibitory eect of a-bulnesene on platelet aggre- gation did not occur due to cytotoxicity. Eect of a-bulnesene on [ 3 H]PAF binding of platelets The total binding of 0.2 nM [ 3 H]PAF to intact rabbit platelets (1.3 10 8 platelets mL 1 ) in the presence of BSA (2.5 mg mL 1 ) was 109131.17 4534.02 dpm (n = 6), whereas the non-specic binding in the presence of 1.5 lM unlabeled PAF was 2339.03 292.18 dpm. As shown in Fig. 3, the a-bulnesene concentration was positively correlated with PAF receptor binding to rabbit washed platelets and also antagonized [ 3 H]PAF binding to intact rabbit platelets. Without adding a-bulnesene to the rabbit washed platelets (control group), [ 3 H]PAF showed 100% binding ability to the PAF receptor. After treatment with dierent concentrations of a-bulnesene (0.5, 5, and 50 lM), [ 3 H]PAF showed a decreased binding ability to the PAF receptor. a-Bulnesene could compete with [ 3 H]PAF for PAF receptor binding. The IC 50 value of a-bulnesene for [ 3 H]PAF binding was 17.62 5.68 lM, and the K i value was 55.81 6.07 nM. In con- trast, 10 lM CV-3988, a specic PAF receptor antagonist, almost completely inhibited [ 3 H]PAF binding ability. The IC 50 value and K i value of CV-3988 were 3.69 0.86 lM and 34.00 7.92 nM, respectively. Eect of a-bulnesene on the intracellular calcium increase of platelets In uo-3-loaded platelets, the resting level for the intracellular Ca 2+ concentration was 61.80 1.04 nM, and PAF (5 nM) caused an increase to 167.01 5.17 nM (Fig. 4a). a-Bulnesene (50 lM) inhibited the PAF-induced intracellular Ca 2+ increase with an IC 50 value of 19.62 1.32 lM (Fig. 4b). Fig. 4c shows that the increase in Ca 2+ release was negatively correlated with the increase in a-bulnesene concentration (12.550 lM). The results shown in Figs. 3 and 4 reveal a similar trend with the a-bulnesene IC 50 values for inhibition of PAF-in- duced platelet aggregation and decreased Ca 2+ release being 17.62 5.68 lM and 19.62 1.32 lM, respectively. This implies that a-bulnesene is able to compete with PAF to bind the PAF receptor and this causes the inhibi- tion of the PAF-induced intracellular calcium increase. Eect of a-bulnesene on thromboxane B 2 and prostaglandin E 2 formation Thromboxane B 2 and prostaglandin E 2 formation in rabbit washed platelets were measured at 6 min after AA was added. As shown in Table 1, the resting level of TXB 2 in rabbit platelets was 7.64 0.40 ng mL 1 . AA (100 lM) markedly increased TXB 2 formation to 568.51 42.63 ng mL 1 . TXB 2 formation stimulated by AA was inhibited by increasing amounts of a-bulnesene (25100 lM). Indomethacin (1 lM) and furegrelate (300 lM) were chosen as positive controls and gave 98.05% and 96.49% inhibition, respectively. On the other hand, PGE 2 was also formed in the presence of AA. PGE 2 formation in the rabbit platelet suspension was 3.45 0.12 ng mL 1 in the unstimulated condition, and AA raised the PGE 2 level to 20.31 0.57 ng mL 1 . PGE 2 formation was inhibited by both a-bulnesene (25100 lM) and indomethacin, but this was reversed with furegrelate (300 lM) (Table 1). Fig. 2. Inhibition trend for dierent concentration of a-bulnesene on the platelet aggregation induced by PAF (5 nM) and AA (100 lM). After washing, the platelets were incubated with isopropanol (0.5%, vehicle) or various concentrations of a-bulnesene at 37 C for 2 min and then the inducer was added to trigger aggregation. Values are expressed as percent inhibition of the aggregation and are presented as means SE (n = 5). Fig. 3. Inhibitory eect of a-bulnesene on [ 3 H]PAF binding to the PAF receptor on rabbit washed platelets. The platelet suspension was incubated with various concentrations of a-bulnesene and [ 3 H]PAF for 2 h. CV-3988 used as positive control. After ltration, the radioactivity was measured. Data are shown as means SE (n = 6). *P < 0.05, **P < 0.01. H.-C. Hsu et al. / Biochemical and Biophysical Research Communications 345 (2006) 10331038 1035 Discussion In this study, we demonstrated that a-bulnesene inhibit- ed platelet aggregation induced by PAF and AA (Fig. 2). Therefore, we further elucidated the detail of inhibitory mechanisms whereby a-bulnesene aects platelet activation caused by these two agonists. PAF is a potent phospholipid mediator that is involved in platelet aggregation, thrombosis, and inammation [18,21,22]. PAF binds to target cells with specic and orga- nized binding kinetics in order to exert its physiological and pathophysiological eects [23]. Inhibition of this spe- cic binding eect reduces the above-mentioned patho- physiological responses. In the platelet aggregation assay (Fig. 2), we observed that a-bulnesene inhibited PAF -induced platelet aggregation. This implied that a-bulne- sene might aect PAF-mediated signal transduction in rabbit platelets. Indeed, a-bulnesene inhibited the specic binding of [ 3 H]PAF to rabbit washed platelets in a dose-dependent fashion (Fig. 3), and the potency was sim- ilar to its inhibiting eect on PAF-induced platelet aggrega- tion. These results suggested that a-bulnesene inhibited platelet aggregation stimulated by PAF through competi- tively inhibiting the binding of PAF to its specic receptor. Using the intracellular Ca 2+ increase assay (Fig. 4), the extent of PAF-elicited intracellular Ca 2+ increase was low- ered progressively by an increase in a-bulnesene, and this data indicated that a-bulnesene blocked the PAF-mediated Ca 2+ increase from the dense-tubular system (DTS) by interfering with the binding between PAF and its receptor. Calcium is an essential second messenger that activates myosin light chain kinase for the induction of the shape change, phospholipase A 2 activation of arachidonic acid release, and platelet aggregation [24]. Rosado et al. [25] recently reported that ethanol reduces thrombin-induced aggregation, which is likely to be due to a signicant inhi- bition of Ca 2+ entry, as well as a reduction in the activity of protein tyrosine kinases. However, in the present study, we deduced that this inhibitory eect of a-bulnesene on plate- let aggregation stimulated by PAF was due to competitive inhibition of the specic binding of PAF to its receptor and this causes a suppression of intracellular Ca 2+ increase. Release of TXA 2 from the activated platelets is an important factor in amplication of the original stimulus Fig. 4. The eect of a-bulnesene on PAF-induced Ca 2+ mobilization. Fluo-3-loaded platelets were pretreated with (a) isopropanol (0.5%) or (b) a-bulnesene (50 lM) at 37 C for 3 min and then activated by 5 nM PAF to trigger [Ca 2+ ] i increase. (c) After PAF induction, the percentage of Ca 2+ released by adding dierent concentrations of a-bulnesene. Data are shown as means SE (n = 5).
P < 0.01. Table 1 Eects of a-bulnesene on TXB 2 and PGE 2 formation induced by AA on rabbit washed platelets Compound TXB 2 formation (ng/mL) PGE 2 formation (ng/mL) Basal 7.64 0.40 3.45 0.12 Control 568.51 42.63 20.31 0.57 Indomethacin (1 lM) 19.93 4.41 ** 7.60 0.32 ** Furegrelate (300 lM) 11.06 0.89 ** 31.65 0.65 ** a-Bulnesene 25 lM 422.96 25.90 ** 18.74 1.42 37.5 lM 366.09 13.72 ** 15.47 0.81 ** 50 lM 292.89 5.53 ** 12.36 0.54 ** 100 lM 160.93 3.76 ** 9.57 0.14 ** Platelet suspension was treated with 0.5% isopropanol (vehicle), 1 lM indomethacin, 300 lM furegrelate or various concentration of a-bulnesene for 2 min. The TXB 2 and PGE 2 formation were induced by 100 lM AA for 6 min and terminated by 1 mM EDTA and 20 lM indomethacin. Following centrifugation, the TXB 2 and PGE 2 levels of the supernatant were measured and expressed as means SE from two independent experiments. ** P < 0.01. 1036 H.-C. Hsu et al. / Biochemical and Biophysical Research Communications 345 (2006) 10331038 due to recruitment of additional platelets from the circula- tion to the site of aggregation [26]. The half-life of TXA 2 is very short, and so the amount of TXB 2 , a stable metabolite of TXA 2 , was measured as an index of TXA 2 formation. According to our data, AA-stimulated PGE 2 and TXB 2 formation were inhibited by a-bulnesene in a concentra- tion-dependent manner (Table 1). This result implied that a-bulnesene decreases TXB 2 and PGE 2 formation primari- ly by inhibiting cyclooxygenase (COX) activity. Thus, a-bulnesene inhibited AA-induced platelet aggregation by blocking of COX activity. When we compared the inhibitory eect of a-bulnesene with CV-3988 on platelet aggregation, we found three phe- nomena. First, both a-bulnesene and CV-3988 have a sim- ilar K i value (55.81 6.07 nM and 34.00 7.92 nM) in the PAF receptor binding assay (Fig. 3). Second, if we compare the results for the PAF binding assay for a-bulnesene and CV-3988, the IC 50 value of a-bulnesene was only ve times lower than that for CV-3988. In addition, a-bulnesene, as the results in Fig. 2 and Table 1 show, is able to inhibit both PAF- and AA metabolite-induced platelet aggrega- tion. However, CV-3988 is only able to inhibit PAF-in- duced platelet aggregation and does not aect COX activity. This implied that a-bulnesene might have poten- tial to be developed as a novel anti-platelet aggregation agent in the future. In conclusion, a-bulnesene is a novel anti-platelet ses- quiterpenoid that acts as a PAF receptor competitive inhib- itor and this would seem to be the predominant method by which there is inhibition of PAF-induced platelet aggrega- tion. Specically, a-bulnesene competitively inhibits the specic binding of PAF to its receptor, thus inhibiting intracellular Ca 2+ increase. However, in addition, a-bulne- sene also possessed an additional inhibitory eect on AA-induced secondary platelet aggregation and TXA 2 formation because the chemical is able to inhibit COX activity. These results indicated that the natural sesquiterp- enoid a-bulnesene has a dual mechanism whereby it acts on platelet aggregation through PAF competitive inhibition and also through inhibition of COX activity. Taken together, our study is highly indicative that a-bulnesene has potential as an anti-platelet agent and deserves further detailed study. Acknowledgment We are grateful to Dr. Kirby for critical reading and comments on the manuscript. References [1] S. Willoughby, A. Holmes, J. Loscalzo, Platelets and cardiovascular disease, Eur. J. Cardiovasc. Nurs. 1 (2002) 273288. [2] C.C. Wu, W.Y. Wang, R.Y. Kuo, F.R. Chang, Y.C. Wu, Antiplatelet eects of KW-7, a new inhibitor of cyclic nucleotide phosphodiester- ases, Eur. J. Pharmacol. 483 (2004) 187194. [3] B.H. Shah, Z. Nawaz, S.A. Pertani, A. Roomi, H. Mahmood, S.A. Saeed, A.H. Gilani, Inhibitory eect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca 2+ signaling, Biochem. Pharmacol. 58 (1999) 11671172. [4] H.C. Chou, J.J. Chen, C.Y. Duh, T.F. Huang, I.S. Chen, Cytotoxic and anti-platelet aggregation constituents from the root wood of Melicope semecarpifolia, Planta Med. 71 (2005) 10781081. [5] S. Pierre, L. Crosbie, A.K. Duttaroy, Inhibitory eect of aqueous extracts of some herbs on human platelet aggregation in vitro, Platelets 16 (2005) 469473. [6] T.T.X. Dong, K.J. Zhao, W.Z. Huang, K.W. Leung, K.W.K. Tsim, Orthogonal array design in optimizing the extraction eciency of active constituents from roots of Panax notoginseng, Phytother. Res. 19 (2005) 684688. [7] M. Miyazawa, Y. Okuno, S. Nakamura, H. Kosaka, Antimutagenic activity of avonoids from Pogostemon cablin, J. Agric. Food Chem. 48 (2000) 642647. [8] W. Tsai, C. Chen, H. Yu, T. Pan, C. Chen, Antiplatelet avones from Pogostemon cablin, Chin. Pharm. J. 47 (1995) 431436. [9] Y. Yang, K. Kinoshita, K. Koyama, K. Takahashi, T. Tai, Y. Nunoura, K. Watanabe, Anti-emetic principles of Pogostemon cablin (Blanco) Benth, Phytomedicine 6 (1999) 8993. [10] Y. Feng, X. Guo, J. Luo, GCMS analysis of volatile oil of Herba Pogostemonis collected from Leizhou county, Zhong Yao Cai 22 (1999) 241243. [11] J. Luo, X. Guo, Y. Feng, Constituents analysis on volatile oil of Pogostemon cablin from dierent collection time cultivated in Hainan, Zhong Yao Cai 25 (2002) 2123. [12] S.L. Munck, R. Croteau, Purication and characterization of the sesquiterpene cyclase patchoulol synthase from Pogostemon cablin, Arch. Biochem. Biophys. 282 (1990) 5864. [13] V. Hernandez, S. Manez, M.C. Recio, R.M. Giner, J.L. Rios, Anti- inammatory prole of dehydrocostic acid, a novel sesquiterpene acid with a pharmacophoric conjugated diene, Eur. J. Pharm. Sci. 26 (2005) 162169. [14] C. Kirana, G.H. McIntosh, I.R. Record, G.P. Jones, Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquit- erpenoid zerumbone, Nutr. Cancer 45 (2003) 218225. [15] T. Yokose, K. Katamoto, S. Park, H. Matsuura, T. Yoshihara, Anti-fungal sesquiterpenoid from the root exudate of Solanum abutiloides, Biosci. Biotechnol. Biochem. 68 (2004) 26402642. [16] G. Hsiao, F.N. Ko, T.T. Jong, C.M. Teng, Antiplatelet action of 3 0 ,4 0 -diisovalerylkhellactone diester puried from Peucedanum japon- icum Thunb, Biol. Pharm. Bull. 21 (1998) 688692. [17] M.L. Selley, J.A. McGuiness, M.R. Bartlett, N.G. Ardlie, Eect of anethole dithiolthione on human platelet aggregation, Arzneimittelf- orschung 42 (1992) 318321. [18] I. Jantan, I.A. Ra, J. Jalil, Platelet-activating factor (PAF) receptor- binding antagonist activity of Malaysian medicinal plants, Phyto- medicine 12 (2005) 8892. [19] F.H. Valone, E. Coles, V.R. Reinhold, E.J. Goetzl, Specic binding of phospholipid platelet-activating factor by human platelets, J. Immu- nol. 129 (1982) 16371641. [20] J.E. Merritt, S.A. McCarthy, M.P. Davies, K.E. Moores, Use of uo- 3 to measure cytosolic Ca 2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buering of cytosolic Ca 2+ , Biochem. J. 269 (1990) 513 519. [21] K.Y. Jung, D.S. Kim, S.R. Oh, S.H. Park, I.S. Lee, J.J. Lee, D.H. Shin, H.K. Lee, Magnone A and B, novel anti-PAF tetrahydrofuran lignans from the ower buds of Magnolia fargesii, J. Nat. Prod. 61 (1998) 808811. [22] H.O. Yang, D.Y. Suh, B.H. Han, Isolation and characterization of platelet-activating factor receptor binding antagonists from Biota orientalis, Planta Med. 61 (1995) 3740. [23] L. Tahraoui, A. Floch, I. Cavero, Functional validation of platelet- activating factor receptor sites characterized biochemically by a specic and reproducible [ 3 H]platelet-activating factor binding in human platelets, J. Pharmacol. Exp. Ther. 252 (1990) 12211227. H.-C. Hsu et al. / Biochemical and Biophysical Research Communications 345 (2006) 10331038 1037 [24] J.W. Heemskerk, P.R. Siljander, E.M. Bevers, R.W. Farndale, T. Lindhout, Receptors and signalling mechanisms in the procoagulant response of platelets, Platelets 11 (2000) 301306. [25] J.A. Rosado, A.M. Nu n ez, J.A. Pariente, G.M. Salido, Alterations in intracellular calcium homeostasis and platelet aggregation induced by ethanol, Biochem. Biophys. Res. Commun. 341 (2006) 917924. [26] G.A. FitzGerald, Mechanisms of platelet activation: thromboxane A 2 as an amplifying signal for other agonists, Am. J. Cardiol. 68 (1991) 11B15B. 1038 H.-C. Hsu et al. / Biochemical and Biophysical Research Communications 345 (2006) 10331038